to test the hypothesis that multi-action compounds, where each bioactive moiety intervenes in several cellular processes, might be more effective than a single agent at killing cancer cells. In particular, “triple action” Pt(IV) derivatives of cisplatin, where the axial ligands are inhibitors of cyclooxygenase (COXi), histone deacetylase (HDACi) or pyruvate dehydrogenase kinase (PDKi) were developed
设计了一系列三重作用的Pt(IV)前药,以检验以下假设:多作用化合物在杀死癌细胞方面可能比单个药剂更有效,其中每个
生物活性部分都参与多个细胞过程。特别是,开发了
顺铂的“三重作用” Pt(IV)衍
生物,其中的轴向
配体是环氧合酶(COXi),组蛋白脱乙酰基酶(H
DACi)或
丙酮酸脱氢酶激酶(PDKi)的
抑制剂。所有化合物ctc- [Pt(NH 3)2(COXi)(PDKi)Cl 2 ],ctc- [Pt(NH 3)2(COXi)(H
DACi)Cl 2 ]和ctc- [Pt(NH 3)2(H
DACi)(PDKi)Cl 2],其中COXi =
阿司匹林或
布洛芬,PDKi =
二氯乙酸盐和H
DACi =
丙戊酸或
丁酸苯酯,对人体内所有
细胞系的细胞毒性均比
顺铂高。在单层细胞毒性试验中,它们对甲状腺和胰腺癌细胞特别有效。值得注意的是,在3D球形癌
细胞培养物中,某些三重作用化合物对KRAS突变的胰腺癌
细胞系(P